Financial Information for the 3rd Quarter of Fiscal Year Ending March 31, 2022 (IFRS)

As of February 3, 2022

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

(Note about forward-looking information)
The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1 Summary of Financial Results for the 3rd Quarter of FY2021 Ending March 31, 2022 and Forecasts for FY2021

(Amounts less than ¥100 million are rounded)

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2021, the forecast is prepared on the assumption that the arbitration procedure to continue.
MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for the 3rd Quarter of FY2021

[Billion yen]

Revenue	299.8	Y-on-Y	9.7	3.3 %
Domestic	248.3	Y-on-Y	6.6	2.7 %
Overseas	51.5	Y-on-Y	3.1	6.4 %

・Domestic ethical drugs sales increased by 2.7% to ¥241.3 bn, due to increase in priority products of STELARA which was additionally approved for the treatment for ulcerative colitis in March 2020 and SIMPONI for Rheumatoid arthritis (RA) treatment etc., despite the negative impact of NHI price revision in April 2021 and generic drugs expansion, and vaccine products decline.
・Sales from overseas increased by 13.7% to ¥42.1 bn, due to increase of Radicava for Amyotrophic Lateral Sclerosis treatment and other products.
・Royalty revenue, etc. decreased by 15.3% to ¥10.5 bn.

[Billion yen]

Core Operating Profit*	7.1	Y-on-Y	(17.6)	(71.2 %)

Core operating profit decreased due to increase of R&D expenses on COVID-19 vaccine and higher sales expenses in the relaxation of voluntary restrictions on activities under COVID-19 spread, etc. despite an increase in sales revenue.

＊With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

[Billion yen]

Operating Profit	10.5	Y-on-Y	65.2	-

Operating profit much increased due to disappearance of ¥84.5 bn impairment loss from NeuroDerm projects for Parkinson's disease booked in FY2020.

[Billion yen]

Net Income Attributable to owners of the Company	6.1	Y-on-Y	51.4	-

2. Summary of Forecasts for FY2021

[Billion yen]

Revenue	398.0	Y-on-Y	20.2	5.4 %
Core Operating Profit	16.5	Y-on-Y	(4.5)	(21.6 %)
Operating Profit	19.5	Y-on-Y	78.0	-
Net Income Attributable to owners of the Company	10.5	Y-on-Y	57.4	-

Forecasts announced on Nov.2 remain unchanged.

2 Consolidated Financial Indicators for the 3rd Quarter of FY2021

(Amounts less than ¥100 million are rounded)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	Q3 FY2021	Comparison to Previous Year			Comparison to Forecasts		Notes [Y-on-Y comparison]
		Q3 FY2020	Increase (decrease)	Change %	Announced on Nov.2, 2021	Progress %	
Revenue	**299.8**	290.2	9.7	3.3	398.0	75.3	Refer to "(2) Sales Revenue of Main Products"
Domestic	**248.3**	241.8	6.6	2.7	307.0	80.9	
Overseas	**51.5**	48.4	3.1	6.4	91.0	56.6	
Overseas sales ratio	**17.2%**	16.7%			22.9%		
Cost of sales	**151.6**	147.2	4.4	3.0	195.0	77.8	
Sales cost ratio	**50.6%**	50.7%			49.0%		
Gross profit	**148.2**	143.0	5.2	3.7	203.0	73.0	
SG&A expenses, etc.	**141.1**	118.2	22.9	19.3	186.5	75.6	
R&D expenses	**70.2**	50.3	19.9	39.6	90.5	77.6	Due mainly to increase in clinical trials costs of global products
Core operating profit	**7.1**	24.7	(17.6)	(71.2)	16.5	43.2	
Non-recurring items*1	**3.4**	(79.5)	82.8	-	3.0	-	Disappeared ¥84.5 impairment loss from NeuroDerm projects, etc. booked in FY2020
Operating profit*1	**10.5**	(54.7)	65.2	-	19.5	53.8	
Net profit attributable to owners of the Company*1	**6.1**	(45.3)	51.4	-	10.5	58.0	

[Yen]

Exchange rate	Q3 FY2021 average	Q3 FY2020 average
USD	**111.45**	105.54

Effect of fluctuations in exchange rate for FY2021 Q3: Revenue increased by around ¥3.3 bn. and core operating profit decreased by around ¥5.5 bn.

(2) Sales Revenue of Main Products

[Billion yen]

	Q3 FY2021	Comparison to Previous Year			Comparison to Forecasts	
		Q3 FY2020	Increase (decrease)	Change %	Announced on Nov.2, 2021	Progress %
Domestic ethical drugs	**241.3**	235.0	6.4	2.7	297.6	81.1
Priority products	**124.4**	103.7	20.7	20.0	153.8	80.9
Stelara	**38.9**	23.0	15.9	69.3	46.4	84.0
Simponi	**33.8**	32.7	1.1	3.2	42.5	79.5
Tenelia	**12.5**	11.8	0.7	5.9	14.8	84.5
Canaglu	**8.8**	8.0	0.8	10.6	10.8	81.8
Canalia	**7.8**	7.5	0.3	4.1	9.5	81.8
Vafseo	**0.7**	0.3	0.4	113.4	1.1	65.5
Lexapro	**11.9**	11.9	0.0	0.3	14.7	80.9
Uplizna	**0.9**	-	0.9	-	1.2	72.4
Rupafin	**5.9**	5.2	0.7	13.7	9.1	65.1
Imusera	**3.1**	3.2	(0.2)	(5.4)	3.6	84.2
Vaccines	**28.5**	36.0	(7.5)	(20.9)	36.3	78.4
Influenza vaccine	**10.7**	13.8	(3.1)	(22.6)	13.5	79.3
Tetrabik	**7.8**	8.2	(0.3)	(4.2)	10.5	74.6
Mearubik	**4.3**	5.1	(0.7)	(14.5)	5.3	81.4
Varicella vaccine	**3.6**	3.8	(0.2)	(6.0)	4.3	83.6
JEBIK V	**1.2**	4.3	(3.2)	(73.2)	1.6	70.9
Long-listed drugs, etc.	**88.5**	95.3	(6.8)	(7.2)	107.5	82.3
Remicade	**31.3**	35.5	(4.2)	(11.9)	38.2	81.8
Overseas ethical drugs	**42.1**	37.0	5.1	13.7	79.2	53.1
Radicava	**18.9**	15.9	3.0	18.7	22.4	84.3
Royalty revenue, etc.	**10.5**	12.4	(1.9)	(15.3)	13.2	79.8
Royalty from INVOKANA	**4.9**	7.4	(2.6)	(34.4)	Undisclosed	–
Royalty from GILENYA*2	**2.9**	3.1	(0.2)	(6.0)	Undisclosed	–

*1: Brackets indicate expense and loss

*2: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of Q3 FY2021	End of FY2020	Increase (decrease)	Notes
Assets	**1,054.9**	1,053.3	1.6	
Non-current assets	**381.9**	378.4	3.5	
Property, plant and equipment	**84.4**	82.1	2.3	Obtain 10.2, depreciation (7.7) etc.
Goodwill	**91.1**	90.6	0.5	
Intangible assets	**92.5**	91.1	1.4	
Current assets	**673.0**	674.8	(1.8)	
Inventories	**74.1**	81.7	(7.6)	
Trade and other receivables	**132.2**	116.0	16.2	
Other financial assets	**326.4**	330.1	(3.7)	
Cash and cash equivalents	**121.2**	114.2	7.0	Refer to "(2) Cash Flow Statement"
Liabilities	**245.0**	236.4	8.6	
Non-current liabilities	**130.1**	108.6	21.5	
Other non-current liabilities	**99.5**	77.5	22.0	
Current liabilities	**114.9**	127.8	(12.9)	
Trade and other payables	**37.1**	29.5	7.6	
Equity	**809.9**	816.9	(7.0)	
Share capital	**50.0**	50.0	-	
Capital surplus	**441.3**	448.0	(6.6)	
Retained earnings	**311.7**	313.3	(1.6)	

(2) Cash Flow Statement

[Billion yen]

	Q3 FY2021	Q3 FY2020	Increase (decrease)
Cash and cash equivalents at beginning of year	**114.2**	83.1	31.2
Cash flows from operating activities	**17.8**	46.8	(29.0)
Profit before tax	**10.9**	(54.5)	65.3
Depreciation and amortization	**10.6**	11.4	(0.8)
Impairment loss	**1.2**	84.5	(83.4)
Loss (Gain) on sales of property, plant and equipment	**(5.2)**	(8.1)	2.9
Trade receivable and payable	**(8.5)**	(24.3)	15.8
Cash flows from investing activities	**6.2**	1.4	4.8
Purchase (proceeds from sales) of property, plant and equipment	**7.2**	(0.4)	7.6
Purchase (proceeds from sales) of investments	**2.4**	64.3	(62.0)
Increase in deposits	**(0.3)**	(65.1)	64.8
Cash flows from financing activities	**(18.4)**	(6.8)	(11.6)
Effect of exchange rate changes on cash and cash equivalents	**1.5**	(0.2)	1.7
Net increase(decrease) in cash and cash equivalents	**7.0**	41.2	(34.2)
Cash and cash equivalents at the end of period	**121.2**	124.3	(3.1)

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

occurring basis	Q3 FY2021	Q3 FY2020	Increase (decrease)
Investment in property, plant and equipment	**10.2**	15.3	(5.1)
Investment in information systems	**1.3**	1.0	0.3

(4) Depreciation and Amortization Costs

[Billion yen]

	Q3 FY2021	Q3 FY2020	Increase (decrease)
Property, plant and equipment	**7.7**	8.4	(0.7)
Intangible assets	**1.0**	0.9	0.1
Intangible assets with products	**2.0**	2.1	(0.1)

3 Forecasts for FY2021

(Amounts less than ¥ 100 million are rounded)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	FY2021 forecasts*2	Comparison to previous year			Notes [Y-on-Y Comparison]
		FY2020 actual	Increase (decrease)	Change %	
Revenue	**398.0**	377.8	20.2	5.4	Refer to "(2) Sales Revenue Forecasts for Main Products"
Domestic	**307.0**	313.0	(6.0)	(1.9)	
Overseas	**91.0**	64.8	26.3	40.6	
Overseas sales ratio	**22.9%**	17.1%			
Cost of sales	**195.0**	190.4	4.6	2.4	
Sales cost ratio	**49.0%**	50.4%			
Gross profit	**203.0**	187.4	15.6	8.3	
SG&A expenses, etc.	**186.5**	166.4	20.1	12.1	Increase due to preparation costs for launch of global products, despite efforts in cost reduction for business productivity
R&D expenses	**90.5**	72.6	17.9	24.7	Increase of clinical trial expenses primarily for global projects
Core operating profit	**16.5**	21.0	(4.5)	(21.6)	
Non-recurring items*1	**3.0**	(79.6)	82.6	-	
Operating profit*1	**19.5**	(58.5)	78.0	-	
Net profit attributable to owners of the Company*1	**10.5**	(46.9)	57.4	-	

Exchange rate

[Yen]

	FY2021 planned	FY2020 average
USD	**110.00**	105.94

(2) Sales Revenue Forecasts for Main Products

[Billion yen]

	FY2021 forecasts*2	Comparison to previous year		
		FY2020 actual	Increase (decrease)	Change %
Domestic ethical drugs	**297.6**	304.7	(7.1)	(2.3)
Priority products	**153.8**	137.7	16.2	11.8
Stelara	**46.4**	32.2	14.2	43.9
Simponi	**42.5**	42.3	0.2	0.4
Tenelia	**14.8**	15.1	(0.3)	(1.7)
Canaglu	**10.8**	10.3	0.5	4.8
Canalia	**9.5**	9.7	(0.2)	(2.1)
Vafseo	**1.1**	0.3	0.7	210.5
Lexapro	**14.7**	15.3	(0.6)	(4.1)
Uplizna	**1.2**	-	1.2	-
Rupafin	**9.1**	8.2	0.9	11.5
Imusera	**3.6**	4.1	(0.5)	(11.2)
Vaccines	**36.3**	42.6	(6.3)	(14.9)
Influenza vaccine	**13.5**	14.4	(0.9)	(6.5)
Tetrabik	**10.5**	10.9	(0.4)	(4.0)
Mearubik	**5.3**	6.1	(0.8)	(13.2)
Varicella vaccine	**4.3**	5.0	(0.7)	(14.0)
JEBIK V	**1.6**	5.2	(3.5)	(68.3)
Long-listed drugs, etc.	**107.5**	124.4	(16.9)	(13.6)
Remicade	**38.2**	45.4	(7.1)	(15.7)
Overseas ethical drugs	**79.2**	50.2	29.0	57.8
Radicava	**22.4**	22.0	0.5	2.2
Royalty revenue, etc.	**13.2**	15.9	(2.7)	(17.1)
Royalty from INVOKANA	**Undisclosed**	9.1	-	-
Royalty from GILENYA*3	**Undisclosed**	4.3	-	-

*1: Brackets indicate expense and loss

*2: Announced on November 2, 2021

*3: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

4 Quarterly Trend

(Amounts less than ¥ 100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2020					FY2021			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Full-year forecasts
Revenue	91.8	95.5	102.9	87.6	377.8	95.4	95.6	108.9	398.0
	24.3%	25.3%	27.2%	23.2%	100.0%	24.0%	24.0%	27.4%	100.0%
Domestic	75.7	79.3	86.7	71.3	313.0	77.0	79.0	92.4	307.0
	24.2%	25.3%	27.7%	22.8%	100.0%	25.1%	25.7%	30.1%	100.0%
Overseas	16.1	16.2	16.1	16.3	64.8	18.4	16.6	16.5	91.0
	24.8%	25.1%	24.9%	25.2%	100.0%	20.2%	18.2%	18.2%	100.0%
Cost of sales	45.6	49.2	52.4	43.2	190.4	47.6	49.2	54.8	195.0
Sales cost ratio	49.7%	51.6%	50.9%	49.3%	50.4%	49.9%	51.4%	50.4%	49.0%
Gross profit	46.2	46.3	50.5	44.4	187.4	47.7	46.4	54.1	203.0
	24.7%	24.7%	26.9%	23.7%	100.0%	23.5%	22.9%	26.6%	100.0%
SG&A expenses, etc.	36.6	41.3	40.3	48.1	166.4	41.9	49.6	49.6	186.5
	22.0%	24.8%	24.2%	28.9%	100.0%	22.5%	26.6%	26.6%	100.0%
R&D expenses	15.3	18.6	16.4	22.3	72.6	18.8	26.4	25.0	90.5
	21.1%	25.6%	22.6%	30.7%	100.0%	20.8%	29.2%	27.6%	100.0%
Core operating profit*	9.6	5.0	10.2	(3.7)	21.0	5.8	(3.2)	4.5	16.5
	45.5%	23.7%	48.4%	(17.6%)	100.0%	35.3%	(19.3%)	27.2%	100.0%
Operating profit*	17.7	(79.6)	7.2	(3.8)	(58.5)	5.8	(4.8)	9.5	19.5
	-	-	-	-	-	29.8%	(24.5%)	48.5%	100.0%
Net profit attributable to owners of the Company*	11.5	(62.4)	5.6	(1.6)	(46.9)	3.1	(4.5)	7.6	10.5
	-	-	-	-	-	29.1%	(43.1%)	72.0%	100.0%

Note: The progress rates show in the lower of each cell, except for "cost of sales".

*Brackets indicate loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2020					FY2021			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Full-year forecasts
Domestic ethical drugs	73.3	77.0	84.7	69.7	304.7	74.5	76.9	89.9	297.6
	24.0%	25.3%	27.8%	22.9%	100.0%	25.1%	25.9%	30.2%	100.0%
Priority products	33.4	33.0	37.3	33.9	137.7	38.9	38.1	47.4	153.8
	24.3%	24.0%	27.1%	24.7%	100.0%	25.3%	24.8%	30.8%	100.0%
Stelara	7.0	7.0	9.1	9.2	32.2	11.4	11.7	15.8	46.4
	21.6%	21.7%	28.1%	28.6%	100.0%	24.6%	25.3%	34.1%	100.0%
Simponi	10.7	10.5	11.5	9.6	42.3	11.1	10.6	12.1	42.5
	25.2%	24.9%	27.3%	22.7%	100.0%	26.1%	24.9%	28.5%	100.0%
Tenelia	4.1	3.9	3.9	3.3	15.1	3.8	4.0	4.7	14.8
	27.2%	25.6%	25.6%	21.6%	100.0%	25.9%	26.7%	31.9%	100.0%
Canaglu	2.5	2.5	3.0	2.3	10.3	3.0	2.7	3.2	10.8
	24.6%	24.3%	28.6%	22.5%	100.0%	27.7%	24.7%	29.4%	100.0%
Canalia	2.5	2.5	2.5	2.2	9.7	2.5	2.4	2.9	9.5
	26.1%	25.4%	25.4%	23.1%	100.0%	26.0%	25.5%	30.4%	100.0%
Vafseo	-	0.3	0.0	0.0	0.3	0.1	0.3	0.4	1.1
	-	88.1%	7.3%	4.7%	100.0%	7.5%	24.3%	33.8%	100.0%
Lexapro	3.9	3.7	4.2	3.5	15.3	3.9	3.7	4.3	14.7
	25.3%	24.4%	27.7%	22.6%	100.0%	26.9%	25.0%	29.1%	100.0%
Uplizna	-	-	-	-	-	0.1	0.2	0.6	1.2
	-	-	-	-	-	10.2%	14.4%	47.8%	100.0%
Rupafin	1.7	1.6	2.0	3.0	8.2	1.9	1.7	2.3	9.1
	20.4%	19.0%	24.4%	36.2%	100.0%	20.5%	18.9%	25.7%	100.0%
Imusera	1.1	1.0	1.1	0.9	4.1	1.1	0.9	1.0	3.6
	26.8%	25.3%	27.1%	20.9%	100.0%	29.6%	25.9%	28.7%	100.0%
Vaccines	7.5	13.6	14.8	6.7	42.6	6.2	11.0	11.3	36.3
	17.6%	31.9%	34.8%	15.6%	100.0%	17.2%	30.2%	31.1%	100.0%
Influenza vaccine	(0.0)	6.4	7.5	0.6	14.4	(0.0)	5.5	5.2	13.5
	(0.2%)	44.1%	52.0%	4.1%	100.0%	(0.0%)	41.1%	38.2%	100.0%
Tetrabik	2.7	2.5	3.0	2.8	10.9	2.6	2.4	2.9	10.5
	24.5%	22.6%	27.7%	25.3%	100.0%	24.5%	22.6%	27.4%	100.0%
Mearubik	1.9	1.8	1.4	1.1	6.1	1.9	1.2	1.2	5.3
	30.9%	29.5%	22.2%	17.3%	100.0%	35.2%	23.0%	23.2%	100.0%
Varicella vaccine	1.3	1.2	1.3	1.2	5.0	1.1	1.1	1.4	4.3
	25.5%	24.8%	26.1%	23.6%	100.0%	26.2%	25.5%	31.9%	100.0%
JEBIK V	1.4	1.5	1.4	0.8	5.2	0.3	0.4	0.5	1.6
	27.9%	28.4%	27.5%	16.1%	100.0%	21.1%	22.0%	27.8%	100.0%
Long-listed drugs, etc.	32.3	30.4	32.6	29.1	124.4	29.4	27.9	31.2	107.5
	26.0%	24.5%	26.2%	23.4%	100.0%	27.4%	25.9%	29.1%	100.0%
Remicade	11.9	11.5	12.1	9.9	45.4	10.4	10.0	10.9	38.2
	26.2%	25.4%	26.6%	21.7%	100.0%	27.3%	26.1%	28.4%	100.0%
Overseas ethical drugs	12.6	12.5	11.9	13.2	50.2	14.4	13.6	14.1	79.2
	25.2%	24.9%	23.7%	26.3%	100.0%	18.2%	17.2%	17.8%	100.0%
Radicava	5.6	5.5	4.9	6.0	22.0	6.3	6.1	6.5	22.4
	25.4%	25.0%	22.1%	27.4%	100.0%	28.3%	27.1%	28.9%	100.0%
Royalty revenue, etc.	3.8	4.1	4.6	3.5	15.9	4.3	3.3	2.9	13.2
	23.6%	25.6%	29.0%	21.8%	100.0%	32.9%	24.9%	22.0%	100.0%
Royalty from INVOKANA	2.0	2.5	2.8	1.7	9.1	1.9	1.6	1.4	Undisclosed
	22.5%	27.8%	31.2%	18.6%	100.0%	-	-	-	-
Royalty from GILENYA[*1]	1.1	0.9	1.2	1.2	4.3	1.1	1.1	0.8	Undisclosed
	24.5%	20.5%	26.8%	28.1%	100.0%	-	-	-	-

Note: The progress rates show in the lower of each cell

*1: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

5 Five-Year Financial Data

(Amounts less than ¥100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q3 FY2021	FY2021 forecasts
Revenues	433.9	424.8	379.8	377.8	299.8	398.0
Cost of sales	169.8	180.6	181.0	190.4	151.6	195.0
Gross profit	264.1	244.1	198.8	187.4	148.2	203.0
SG&A expenses, etc.	185.6	188.3	179.7	166.4	141.1	186.5
R&D expenses	79.1	86.5	79.4	72.6	70.2	90.5
Core operating profit	78.5	55.8	19.1	21.0	7.1	16.5
Operating profit	77.3	50.3	(6.1)	(58.5)	10.5	19.5
Net profit attributable to owners of the Company	58.0	37.4	0.1	(46.9)	6.1	10.5

(2) Balance Sheet

[Billion yen]

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q3 FY2021
Assets	1,048.4	1,056.3	1,046.3	1,053.3	1,054.9
Non-current assets	462.9	467.9	452.8	378.4	381.9
Current assets	585.5	588.4	593.5	674.8	673.0
Liabilities	153.6	146.0	188.4	236.4	245.0
Non-current liabilities	55.4	54.3	90.3	108.6	130.1
Current liabilities	98.2	91.7	98.0	127.8	114.9
Equity	894.8	910.3	857.9	816.9	809.9

(3) Other Financial Data

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q3 FY2021	FY2021 forecasts
Cash flows from operating activities	66.9	41.5	49.4	67.8	17.8	-
Cash flows from investing activities	(19.2)	(31.2)	(39.2)	(31.9)	6.2	-
Cash flows from financing activities	(32.5)	(25.9)	(37.9)	(7.2)	(18.4)	-
Investments in property, plant and equipment	6.2	8.6	15.5	20.0	11.4	15.7
Depreciation and Amortization Costs	11.5	11.5	10.9	15.2	10.6	13.6
Property, plant and equipment	7.6	7.1	7.0	11.1	7.7	9.8
Intangible assets including intangible assets with products	4.0	4.4	4.0	4.1	2.9	3.8
Ratio of equity attributable to owners of the Company to total assets [%]	84.2	85.0	81.4	76.9	76.1	-
ROE [%]	6.6	4.2	0.0	(5.6)	-	-
Basic earnings per share [¥]	103.35	66.64	0.26	(83.58)	-	-
Equity attributable to owners of the Company per share [¥]	1,574.26	1,600.64	1,519.22	1,443.99	1,430.55	-

(4) Number of Employees

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q3 FY2021	Forecasts for end of FY2021
Consolidated	7,187	7,228	6,987	6,728	6,725	7,100
Non-consolidated	4,222	4,111	3,764	3,383	3,292	3,420

6 State of New Product Development (As of January 25, 2022)

(1) Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Bipolar disorder)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Licensed from Horizon Therapeutics (Ireland)
	(Myasthenia gravis)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
		Asia Filed	
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	US Filed* (Jan. 2022)	In-house
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Peripheral neuropathic pain)	Japan Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921 (Unasnemab)	Anti-RGMa antibody (Spinal cord injury)	Global Phase 2	Co-developed with Osaka University (Japan)

* Development stage for other countries excluding US is Phase 3

(2) Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-5547 (Fasinumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
	(Systemic sclerosis)	Global Phase 2	
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (IgG4-related disease)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

※ Asia: Excluding Japan and China

(3) Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-2766	Plant-derived VLP vaccine (Prophylaxis of COVID-19)	Canada Filed* (Dec. 2021)	Medicago product (Canada)
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-8972	Plant-derived VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-derived VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-derived VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2654	Adjuvanted plant-derived VLP vaccine (Prophylaxis of seasonal influenza/elderly)	Phase 1	Medicago product (Canada)

* Development stage for other countries excluding Canada is Phase 3

(4) Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Chronic kidney disease with type 2 diabetes mellitus)	Japan Filed (Aug. 2021)	In-house
MT-6548 Vafseo (Vadadustat)	Hypoxia-inducible factor prolyl hydroxylase inhibitor (Renal anemia)	Asia Filed (Jan. 2022)	Licensed from Akebia (US)
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-2765	Renin inhibitor (Hypertension)	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-8633/TR1801-ADC	Anti-c-Met antibody drug conjugate (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

※ Asia: Excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of Jan. 25, 2022	Origin / licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	Malaysia Approved (Dec. 2021)	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Bipolar disorder)	Asia Filed	Singapore Approved (Jan. 2022)	Licensed from Gedeon Richter (Hungary)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Asia Filed	Korea Approved (Nov. 2021) Indonesia Approved (Dec. 2021)	Licensed from Neurocrine Biosciences (US)
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	US Filed* (Jan. 2022)	In-house
MT-2766	Plant-derived VLP vaccine (Prophylaxis of COVID-19)	Global Phase 3	Canada Filed** (Dec. 2021)	Medicago product (Canada)
MT-6548 Vafseo (Vadadustat)	Hypoxia-inducible factor prolyl hydroxylase inhibitor (Renal anemia)	None	Asia Filed (Jan. 2022)	Licensed from Akebia (US)
MT-8554 (Elismetrep)	TRPM8 antagonist (Peripheral neuropathic pain)	Europe Phase 2	Japan Phase 2	In-house

* Development stage for other countries excluding US is Phase 3

** Development stage for other countries excluding Canada is Phase 3

※ Asia: excluding Japan and China